The IP Federation has responded to the IPO consultation with deadline 31 July 2011.

We strongly support any change to the law that will improve the current UK regulatory framework by removing the risk of patent infringement when carrying out clinical and field trials involving pharmaceuticals. The ultimate aim should be to harmonise law throughout the EU in this area, but until this happens we advocate changing the UK patent law unilaterally to exempt from infringement all activities relating to regulatory approval of a drug product.

For full details, click HERE.

To see all our policy papers, click HERE.